No, it's a penny stock, that's why. I've been in companies that had very revolutionary science, no coverage so long as they were a penny stock. Coverage of the scientists though. Just like here. But LL is not doing fundamental cell research, like how to reprogram or clone a cell.
This is a trial, in process, not yet revealed, so different kind of coverage.
Plus there was too much energy thrown at the company to discredit it, DCVax-L and anyone involved with it. That also doesn't help, and those who engage in such activities know that to be the case for these tiny "penny stocks". Most large media companies have strict rules about covering "penny stocks". They are all tarred with the same brush, regardless of obvious legitimacy.
However, these rules have NOT applied to the research with regard to UK coverage. The UK just looks at the science and says this is incredible. They do not typically post the stock ticker however, again they mostly just talk about DCVax-L. And, to be honest, there have been plenty of references to DCVax-L in just about any recent survey of Glioblastoma treatments, which is what this trial is for. Additionally, there were a number of mainstream articles following the UK coverage. But there is no news to report until there are final results reported. That has not happened yet. What do you want them to "cover"?
The only folks that cover companies that are quiet are what I refer to as the short stalker press. They often try to get out ahead of good news with unfavorable coverage. We all know what reporters would be counted amongst those reporters. But I think some of them know that in the current climate, and with their past activities, they are under an immense cloud of suspicion and such coverage would probably ruin their reputations forever, if not lead to charges.
